Insmed Incorporated Forecast, price target & analysts
Insmed Incorporated Target price 2026 - Analyst rating & recommendation
Insmed Incorporated Classifications & Recommendation
Insmed Incorporated Price Target
| Target Price | $200.43 |
| Price | $111.59 |
| Potential | 79.61% |
| Number of Estimates | 25 |
| 25 Analysts have issued a price target Insmed Incorporated 2027 . The average Insmed Incorporated target price is $200.43. This is 79.61% higher than the current stock price. The highest price target is $255.15 128.65% , the lowest is $166.65 49.34% . | |
| A rating was issued by 30 analysts: 29 Analysts recommend Insmed Incorporated to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Insmed Incorporated stock has an average upside potential 2027 of 79.61% . Most analysts recommend the Insmed Incorporated stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
26 Analysts have issued a sales forecast Insmed Incorporated 2026 . The average Insmed Incorporated sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
9 Analysts have issued an Insmed Incorporated EBITDA forecast 2026. The average Insmed Incorporated EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
26 Insmed Incorporated Analysts have issued a net profit forecast 2026. The average Insmed Incorporated net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
26 Analysts have issued a Insmed Incorporated forecast for earnings per share. The average Insmed Incorporated EPS is
. This is than earnings per share in the financial year 2025. The highest EPS forecast is , the lowest is .This results in the following potential growth metrics and future valuations:
Insmed Incorporated...
Current Insmed Incorporated Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Oct 21 2026 |
| Wolfe Research |
Outperform
➜
Peer Perform
|
Downgrade | Oct 12 2026 |
| HC Wainwright & Co. |
Buy
➜
Buy
|
Unchanged | Oct 12 2026 |
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Sep 30 2026 |
| Goldman Sachs |
➜
Buy
|
Unchanged | Sep 24 2026 |
| Roth Capital |
Buy
➜
Buy
|
Unchanged | Sep 15 2026 |
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Aug 10 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Oct 21 2026 |
|
Downgrade
Wolfe Research:
Outperform
➜
Peer Perform
|
Oct 12 2026 |
|
Unchanged
HC Wainwright & Co.:
Buy
➜
Buy
|
Oct 12 2026 |
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Sep 30 2026 |
|
Unchanged
Goldman Sachs:
➜
Buy
|
Sep 24 2026 |
|
Unchanged
Roth Capital:
Buy
➜
Buy
|
Sep 15 2026 |
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Aug 10 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
